The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.

The FDA has expanded the approval of Addyi to include the treatment of hypoactive sexual desire disorder in women less than 65 years.

Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.

Experts highlight how nurse practitioners can use lifestyle medicine and nutrition to reduce chronic disease and improve outcomes.

Credit: Flow Neuroscience. Investigators aimed to evaluate cranial electrotherapy stimulation for moderate to severe MDD in nonrefractory patients. The at-home brain stimulation device is expected to ...

Genetic analysis of impulsive traits reveals heterogeneous underpinnings, challenging the notion of a single construct. The genetic underpinnings of impulsivity are heterogeneous, suggesting that is ...